Determination of a Normal Level of Serum CA125 in Postmenopausal Women as a Tool for Preoperative Evaluation and Postoperative Surveillance of Endometrial Carcinoma

Kurihara, Terumasa; Mizunuma, Hideki; Obara, Mitsuo; Andoh, Kazumichi; Ibuki, Yoshito; Nishimura, Toshinobu

doi:10.1006/gyno.1998.5018

Cited by 74 publications

(47 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More importantly, TFF3 serum levels showed higher sensitivity in the detection of patients harbouring G3-EEC when compared with CA125 (cutoff ¼ 35 U ml À1 ). Furthermore, similar results were found when CA125 was compared with TFF3 levels at a cutoff value of 20 U ml À1 , reported by several investigators to be more appropriate for preoperative evaluation and post-operative surveillance of EC patients (Sood et al, 1997;Kurihara et al, 1998). Indeed, even at this lower CA125 setting, TFF3 remained a more sensitive indicator of tumour presence than CA125.…”

Section: Discussionsupporting

confidence: 80%

Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas

et al. 2008

View full text Add to dashboard Cite

This study identifies the genetic fingerprint of poorly differentiated endometrioid endometrial carcinomas (G3-EEC) and analyses the potential utility of trefoil factor 3 (TFF3) as novel serum marker in G3-EEC. Affymetrix microarrays were used to identify the gene expression patterns of 19 snap-frozen G3-EEC and 15 normal endometrium (NE) biopsies. Quantitative real-time PCR (qRT-PCR) and immunohistochemistry were used to validate TFF3 expression. Finally, TFF3 serum levels were determined by ELISA in 25 G3-EEC patients, 42 healthy controls, and in 13 endometrial hyperplasia patients. Hierarchical cluster analysis showed TFF3 as the top differentially expressed gene between 363 upregulated genes in G3-EEC, when compared with NE. Trefoil factor 3 gene expression levels analysed by qRT-PCR significantly correlated with Affymetrix results (Po0.001; rs ¼ 0.85). By immunohistochemistry, TFF3 protein was significatively more expressed in EEC compared with NE (Po0.01), with cytoplasmatic positivity in 79% G3-EEC and 18% NE. Patients harbouring G3-EECs had significantly higher TFF3 serum concentration by ELISA when compared with healthy patients (Po0.001) or patients harbouring endometrial hyperplasia (P ¼ 0.012). In conclusion, TFF3 is highly expressed at gene and protein level in G3-EEC. Further investigations on a wider set of samples are warranted to validate TFF3 as a novel serum marker for early detection and/or monitoring of G3-EEC patients.

show abstract

Section: Discussionsupporting

confidence: 80%

Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Kurihara et al demonstrated in a small study that CA-125 was higher among healthy post-menopausal women using hormone therapy than among nonusers. [24] Two clinical trials examined CA-125 levels in response to initiation of hormone therapy. [25;26] In both studies there was no effect of current estrogen therapy on CA-125 levels in women with hysterectomies, which corroborates our data.…”

Section: Discussionmentioning

confidence: 99%

The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial

Johnson

Kessel

Riley³

et al. 2008

Gynecologic Oncology

View full text Add to dashboard Cite

Objective-To determine the epidemiology of CA-125 in women without ovarian cancer.Methods-We analyzed demographic, medical and lifestyle characteristics related to CA-125, measured using the Centocor CA-125II RIA assay, among 25,608 multi-ethnic U.S. women aged 55-74 years enrolled in a cancer screening trial and found to have no evidence of ovarian cancer.Results-Mean CA-125 level was 11.9 U/ml (SD 8.3); median 10.0 U/ml, interquartile range 8.0-14.0. High levels, using the clinical cut point of ≥ 35 U/ml, were associated with increased age (p<0.001) and former smoking (p<0.021), while hysterectomy and obesity were protective (p<0.001). Mean levels were higher with increasing age (p<0.001), ever use of hormone therapy (p<0.001), former smoking (p<0.017) and history of breast cancer (p<0.002), but lower (p<0.001) with non-White status, previous hysterectomy, current smoking, and obesity. Current hormone therapy use was not associated with CA-125 in women without a uterus.Conclusion-In post-menopausal women without ovarian cancer, CA-125 level is influenced by a number of factors, including race/ethnicity, age, hysterectomy, smoking history and obesity.

show abstract

“…For nearly 3 decades, carbohydrate antigen 125 (CA125) has been used as a biomarker to assist the detection and monitoring of ovarian and endometrial cancers [1][2][3]. However, CA125 level is much affected by many physiological and benign conditions, which compromises its sensitivity and specificity [4].…”

Section: Introductionmentioning

confidence: 99%

Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies

Duan

et al. 2016

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Determination of a Normal Level of Serum CA125 in Postmenopausal Women as a Tool for Preoperative Evaluation and Postoperative Surveillance of Endometrial Carcinoma

Cited by 74 publications

References 21 publications

Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas

Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas

The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial

Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies

Contact Info

Product

Resources

About